Trial Outcomes & Findings for PED NEONAT 20-000599 Fetal Body Composition (NCT NCT04508751)
NCT ID: NCT04508751
Last Updated: 2023-08-30
Results Overview
MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images and PDFF maps. The FB-MRI radial data will be transferred to a separate workstation for custom reconstruction of 3D fat-water-separated images and PDFF maps and analysis. Visceral adipose tissue PDFF values will be directly measured from regions of interest.
COMPLETED
PHASE1
23 participants
During the procedure (MRI)
2023-08-30
Participant Flow
Recruited by study investigator or obstetrician through medical clinic.
One subject was excluded due to inability to schedule MRI scan
Participant milestones
| Measure |
Healthy Pregnancy
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded.
3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
|
Pregnant Mothers With Gestational Diabetes
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded.
3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
|
Pregnant Mothers With Infants Diagnosed With IUGR
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded.
3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
|
|---|---|---|---|
|
Overall Study
STARTED
|
10
|
5
|
7
|
|
Overall Study
COMPLETED
|
10
|
5
|
5
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
2
|
Reasons for withdrawal
| Measure |
Healthy Pregnancy
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded.
3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
|
Pregnant Mothers With Gestational Diabetes
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded.
3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
|
Pregnant Mothers With Infants Diagnosed With IUGR
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded.
3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
|
|---|---|---|---|
|
Overall Study
Discontinued study early due to maternal discomfort
|
0
|
0
|
2
|
Baseline Characteristics
PED NEONAT 20-000599 Fetal Body Composition
Baseline characteristics by cohort
| Measure |
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
|
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
|
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
|
Total
n=20 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
34.5 years
n=5 Participants
|
33 years
n=7 Participants
|
35 years
n=5 Participants
|
34.5 years
n=4 Participants
|
|
Sex: Female, Male
Female
|
10 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
20 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
7 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
8 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
13 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Asian
|
3 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
White
|
7 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
15 Participants
n=4 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Region of Enrollment
United States
|
10 participants
n=5 Participants
|
5 participants
n=7 Participants
|
5 participants
n=5 Participants
|
20 participants
n=4 Participants
|
|
Glucose tolerance test at 1 hour
|
87 mg/dL
n=5 Participants
|
182 mg/dL
n=7 Participants
|
131 mg/dL
n=5 Participants
|
109 mg/dL
n=4 Participants
|
PRIMARY outcome
Timeframe: During the procedure (MRI)MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images and PDFF maps. The FB-MRI radial data will be transferred to a separate workstation for custom reconstruction of 3D fat-water-separated images and PDFF maps and analysis. Visceral adipose tissue PDFF values will be directly measured from regions of interest.
Outcome measures
| Measure |
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
|
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
|
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
|
|---|---|---|---|
|
Maternal Visceral Adipose Tissue Volume
|
97593 mm3
Interval 78014.0 to 121081.0
|
169626 mm3
Interval 137736.0 to 227035.0
|
96787 mm3
Interval 82327.0 to 184784.0
|
PRIMARY outcome
Timeframe: During the procedure (MRI)MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images. The distribution/extent of hepatic fat will be manually delineated/drawn on the 3D MRI images and PDFF maps. This work will be performed by PI Strobel with validation from PI Wu.
Outcome measures
| Measure |
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
|
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
|
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
|
|---|---|---|---|
|
Fetal Liver PDFF
|
3.2 percentage of triglycerides/
Interval 3.0 to 3.3
|
5.2 percentage of triglycerides/
Interval 4.2 to 5.5
|
1.9 percentage of triglycerides/
Interval 1.4 to 3.7
|
SECONDARY outcome
Timeframe: During the procedure (MRI)MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images and PDFF maps. The FB-MRI radial data will be transferred to a separate workstation for custom reconstruction of 3D fat-water-separated images and PDFF maps and analysis. Subcutaneous adipose tissue PDFF values will be directly measured from regions of interest.
Outcome measures
| Measure |
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
|
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
|
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
|
|---|---|---|---|
|
Fetal Subcutaneous Tissue Volume
|
241 mm3
Interval 232.0 to 255.0
|
280 mm3
Interval 261.0 to 295.0
|
220 mm3
Interval 205.0 to 235.0
|
SECONDARY outcome
Timeframe: During the procedure (MRI)MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images. The distribution/extent of subcutaneous fat will be manually delineated/drawn on the 3D MRI images and PDFF maps and used to calculate volume of subcutaneous adipose tissue. This work will be performed by PI Strobel with validation from PI Wu.
Outcome measures
| Measure |
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
|
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
|
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
|
|---|---|---|---|
|
Maternal Subcutaneous Tissue Volume
|
157319 mm3
Interval 126300.0 to 200028.0
|
216264 mm3
Interval 161461.0 to 325975.0
|
159197 mm3
Interval 84024.0 to 339707.0
|
SECONDARY outcome
Timeframe: During the procedure (MRI)MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images and PDFF maps. The FB-MRI radial data will be transferred to a separate workstation for custom reconstruction of 3D fat-water-separated images and PDFF maps and analysis. Hepatic adipose tissue PDFF values will be directly measured from regions of interest.
Outcome measures
| Measure |
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
|
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
|
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
|
|---|---|---|---|
|
Maternal Hepatic Fat PDFF
|
2.1 % triglycerides
Interval 1.8 to 2.8
|
3.2 % triglycerides
Interval 2.1 to 3.8
|
2.2 % triglycerides
Interval 1.1 to 5.0
|
Adverse Events
Healthy Pregnancy
Pregnant Mothers With Gestational Diabetes
Pregnant Mothers With Infants Diagnosed With IUGR
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place